Header Logo

Connection

HASHEM EL-SERAG to Hepatitis C

Back to Details
This is a "connection" page, showing publications HASHEM EL-SERAG has written about Hepatitis C.
HASHEM EL-SERAG
Connection Strength
10.553
Hepatitis C
  1. Bioimpedance analysis predicts the etiology of cirrhosis in a prospective cohort study. Hepatol Commun. 2023 10 01; 7(10).
    View in: PubMed
    Score: 0.653
  2. Risk factors for HCC in contemporary cohorts of patients with cirrhosis. Hepatology. 2023 03 01; 77(3):997-1005.
    View in: PubMed
    Score: 0.628
  3. The effects of sustained virological response to direct-acting anti-viral therapy on the risk of extrahepatic manifestations of hepatitis C infection. Aliment Pharmacol Ther. 2019 06; 49(11):1442-1447.
    View in: PubMed
    Score: 0.480
  4. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology. 2017 10; 153(4):996-1005.e1.
    View in: PubMed
    Score: 0.424
  5. ?Ongoing alcohol consumptions counteracts the benefits of sustained virological response in patients with well compensated hepatitis C cirrhosis: an observational study. Ann Hepatol. 2017 Jan-Feb 2017; 16(1):16-20.
    View in: PubMed
    Score: 0.411
  6. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology. 2016 07; 64(1):130-7.
    View in: PubMed
    Score: 0.391
  7. The Updated Model: An Adjusted Serum Alpha-Fetoprotein-Based Algorithm for Hepatocellular Carcinoma Detection With Hepatitis C Virus-Related Cirrhosis. Gastroenterology. 2015 Dec; 149(7):1986-7.
    View in: PubMed
    Score: 0.379
  8. A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis. Gastroenterology. 2014 May; 146(5):1249-55.e1.
    View in: PubMed
    Score: 0.335
  9. Prevalence and predictors of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. Hepatology. 2013 Aug; 58(2):538-45.
    View in: PubMed
    Score: 0.322
  10. CDC and USPSTF 2012 recommendations for screening for hepatitis C virus infection: overview and take-home messages. Gastroenterology. 2013 Mar; 144(3):478-81.
    View in: PubMed
    Score: 0.315
  11. Finasteride and methadone use and risk of advanced hepatitis C related liver disease. Dig Dis Sci. 2012 Nov; 57(11):3004-10.
    View in: PubMed
    Score: 0.299
  12. Determinants of serum alpha-fetoprotein levels in hepatitis C-infected patients. Clin Gastroenterol Hepatol. 2012 Apr; 10(4):428-33.
    View in: PubMed
    Score: 0.289
  13. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med. 2011 Jan 18; 154(2):85-93.
    View in: PubMed
    Score: 0.272
  14. Achieving health equity to eliminate racial, ethnic, and socioeconomic disparities in HBV- and HCV-associated liver disease. J Fam Pract. 2010 Apr; 59(4 Suppl):S37-42.
    View in: PubMed
    Score: 0.257
  15. Statin therapy and serum transaminases among a cohort of HCV-infected veterans. Dig Dis Sci. 2010 Jan; 55(1):190-5.
    View in: PubMed
    Score: 0.253
  16. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans. Hepatology. 2009 Jan; 49(1):116-23.
    View in: PubMed
    Score: 0.236
  17. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol. 2008 Nov; 49(5):831-44.
    View in: PubMed
    Score: 0.230
  18. Effect of human immunodeficiency virus and antiretrovirals on outcomes of hepatitis C: a systematic review from an epidemiologic perspective. Clin Gastroenterol Hepatol. 2007 Nov; 5(11):1321-1328.e7.
    View in: PubMed
    Score: 0.218
  19. Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era. J Hepatol. 2005 Mar; 42(3):309-14.
    View in: PubMed
    Score: 0.181
  20. Utility of a depression score to predict candidacy for hepatitis C virus therapy in veterans: a prospective longitudinal study. Aliment Pharmacol Ther. 2005 Feb 01; 21(3):235-42.
    View in: PubMed
    Score: 0.180
  21. The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am J Gastroenterol. 2005 Jan; 100(1):56-63.
    View in: PubMed
    Score: 0.179
  22. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992-2001. Arch Intern Med. 2004 Nov 22; 164(21):2349-54.
    View in: PubMed
    Score: 0.178
  23. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004 Nov; 127(5 Suppl 1):S27-34.
    View in: PubMed
    Score: 0.177
  24. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology. 2004 Nov; 127(5):1372-80.
    View in: PubMed
    Score: 0.177
  25. Association between hepatitis C infection and other infectious diseases: a case for targeted screening? Am J Gastroenterol. 2003 Jan; 98(1):167-74.
    View in: PubMed
    Score: 0.156
  26. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology. 2002 Nov; 36(5 Suppl 1):S74-83.
    View in: PubMed
    Score: 0.154
  27. Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States. J Clin Gastroenterol. 2002 Sep; 35(3):266-9.
    View in: PubMed
    Score: 0.152
  28. Longitudinal Associations of Risk Factors and Hepatocellular Carcinoma in Patients With Cured Hepatitis C Virus Infection. Am J Gastroenterol. 2022 11 01; 117(11):1834-1844.
    View in: PubMed
    Score: 0.152
  29. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology. 2002 Aug; 123(2):476-82.
    View in: PubMed
    Score: 0.151
  30. Admixture Mapping in African Americans Identifies New Risk Loci for HCV-Related Cirrhosis. Clin Gastroenterol Hepatol. 2023 04; 21(4):1023-1030.e39.
    View in: PubMed
    Score: 0.150
  31. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metab. 2022 07 05; 34(7):969-977.e2.
    View in: PubMed
    Score: 0.150
  32. Treatment of hepatitis C virus infection in people with opioid use disorder: a real-world study of elbasvir/grazoprevir in a US Department of Veterans Affairs population. Am J Drug Alcohol Abuse. 2022 07 04; 48(4):445-453.
    View in: PubMed
    Score: 0.146
  33. Interferon: benefit beyond hepatitis therapy? Am J Gastroenterol. 2001 Dec; 96(12):3435-6.
    View in: PubMed
    Score: 0.144
  34. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med. 2000 Nov 27; 160(21):3227-30.
    View in: PubMed
    Score: 0.135
  35. Epidemiology of Hepatocellular Carcinoma. Hepatology. 2021 01; 73 Suppl 1:4-13.
    View in: PubMed
    Score: 0.135
  36. Real-world effectiveness of elbasvir/grazoprevir In HCV-infected patients in the US veterans affairs healthcare system. J Viral Hepat. 2018 11; 25(11):1270-1279.
    View in: PubMed
    Score: 0.114
  37. Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteran's Affairs Health Care System. BMC Med Res Methodol. 2018 01 04; 18(1):1.
    View in: PubMed
    Score: 0.110
  38. Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents. Aliment Pharmacol Ther. 2017 11; 46(10):992-1000.
    View in: PubMed
    Score: 0.108
  39. Hepatitis C virus-related complications are increasing in women veterans: A national cohort study. J Viral Hepat. 2017 11; 24(11):955-965.
    View in: PubMed
    Score: 0.107
  40. Race and Gender Differences in the Use of Direct Acting Antiviral Agents for Hepatitis C Virus. Clin Infect Dis. 2016 08 01; 63(3):291-9.
    View in: PubMed
    Score: 0.098
  41. Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice. Clin Gastroenterol Hepatol. 2015 Nov; 13(12):2140-51.
    View in: PubMed
    Score: 0.093
  42. Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. Hepatology. 2014 Dec; 60(6):1871-8.
    View in: PubMed
    Score: 0.088
  43. The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther. 2014 Mar; 39(5):518-31.
    View in: PubMed
    Score: 0.084
  44. Hepatocellular carcinoma screening practices in the Department of Veterans Affairs: findings from a national facility survey. Dig Dis Sci. 2013 Nov; 58(11):3117-26.
    View in: PubMed
    Score: 0.081
  45. Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and nonpatient factors. Hepatology. 2013 May; 57(5):1858-68.
    View in: PubMed
    Score: 0.079
  46. Alpha-fetoprotein should be included in the hepatocellular carcinoma surveillance guidelines of the American Association for the Study of Liver Diseases. Hepatology. 2011 Mar; 53(3):1060-1; author reply 1061-2.
    View in: PubMed
    Score: 0.068
  47. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis. 2010 Jul; 42 Suppl 3:S206-14.
    View in: PubMed
    Score: 0.065
  48. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010 Feb; 138(2):513-21, 521.e1-6.
    View in: PubMed
    Score: 0.062
  49. The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases. Aliment Pharmacol Ther. 2008 Feb 01; 27(3):274-82.
    View in: PubMed
    Score: 0.054
  50. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA. 2007 May 09; 297(18):2010-7.
    View in: PubMed
    Score: 0.053
  51. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study. Am J Gastroenterol. 2007 May; 102(5):1016-21.
    View in: PubMed
    Score: 0.052
  52. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003 Nov 18; 139(10):817-23.
    View in: PubMed
    Score: 0.041
  53. The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans. Am J Gastroenterol. 2001 Aug; 96(8):2462-7.
    View in: PubMed
    Score: 0.035
  54. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2001 Feb; 5(1):87-107, vi.
    View in: PubMed
    Score: 0.034
  55. Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol. 2013 Aug; 108(8):1314-21.
    View in: PubMed
    Score: 0.020
  56. Hepatocellular carcinoma at the cutting edge of science and practice. Minerva Med. 2010 Dec; 101(6):391-3.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.